Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Imatinib/Sunitinib-Resistant GIST
NCT01289028Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Started Nov 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01289028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289028.